“Synthetic Embryos”: The Wrong Term For Important New Research

“Synthetic Embryos”: The Wrong Term For Important New Research

This fluorescent image shows a representative post-implantation amniotic sac embroid.

(Courtesy of Yue Shao)


Keep Reading Keep Reading
Norbert Gleicher
Dr. Norbert Gleicher founded the Center for Human Reproduction (CHR) in 1981, after completing his residency at the Mount Sinai School of Medicine in New York and holding top academic and administrative positions in various academic institutions in New York and Chicago. Always keen on simultaneously pursuing clinical care and research, Dr. Gleicher has published hundreds of peer-reviewed medical journal articles, abstracts and book chapters, in addition to editing textbooks that are now regarded as classics. Dr. Gleicher also holds adjunct professorship appointments at Rockefeller University in New York City, as well as Medical University Vienna.
Get our top stories twice a month
Follow us on
Sexually Transmitted Infections are on the rise. This drug could stop them.

Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.

Adobe Stock

Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.

It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.
The Friday Five: The plain solution to holiday stress?

In this week's Friday Five, research on how to improve your working memory, the plain old solution to stress, rise of the robot surgeon, tomato brain power, the gut connection to health after strokes - and more.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.